Alvotech
ALVO
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.8B
$5.32
▼ -1.12%
P/E
-9.10
Mkt Cap
$1.8B
52-Wk Range
$2.94–$9.25
52-Week Range
$2.94 - $9.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 34.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced high-concentration formulation technology for improved patient compliance
- Strategic focus on high-value, blockbuster drug biosimilars with substantial addressable markets
- Diversified pipeline across multiple therapeutic areas reducing revenue concentration risk
- Established manufacturing capabilities and regulatory expertise in biosimilar development
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Moderate growth ahead
FDA and EMA approvals for lead candidates expanding commercial revenue streams
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+25.5% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ALVO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 19, 2026
Reported EPS of -$0.11 vs -$0.05 consensus (-109.1% surprise). Revenue of $106.0M vs $103.0M expected (+2.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-109.1%
Revenue trend · last 8Q
—
—
+260%
-13%
+11%
+10%
-20%
-39%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$102.9M
$151.2M
$132.8M
$173.2M
$114.0M
$166.4M
$105.9M
$105.8M
Margins · last 8Q
Gross
50.6%
Operating
-11.2%
Profit
-63.2%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
0%
Sell
25%
Median Price Target
—
Latest: Bank of America · Aug 24, 2026
vs Industry
How ALVO stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related